Gut-selective & IL-12/23 biologics (IBD)
Immunology· 2 reviewed drugs· 3130 cited findings behind them
What the regulatory reviews cover
The library includes two biologics reviewed by regulatory bodies for inflammatory bowel disease (IBD): Stelara and Entyvio. Stelara was reviewed for adult patients with moderately to severely active ulcerative colitis, moderate to severe plaque psoriasis, and moderate to severe Crohn’s disease. Entyvio was reviewed for adults with moderately to severely active ulcerative colitis.
Different drugs were studied in different trials, so figures are not head-to-head. For Stelara, Clinical Response at Week 6 (Induction Study 3002) was 55.5%. For Entyvio, Clinical remission at Week 52 (treatment difference vs placebo) was 32.
The drugs — one cited result each
| Stelara Johnson & Johnson | Clinical Response at Week 6 (Induction Study 3002): 55.5 % Johnson & Johnson — Stelara FDA Review (BLA761044, ORIG 1, 2, p.114 |
| Entyvio Takeda Pharmaceutical Company Limited | Clinical remission at Week 52 (treatment difference vs placebo): 32 Takeda Pharmaceutical Company Limited — Entyvio FDA Review, p.48 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Immunology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.